Targeting triple-negative breast cancer: optimising therapeutic outcomes

被引：141
|
作者：
Gelmon, K. [1 ,2 ]
Dent, R. [3 ,4 ]
Mackey, J. R. [5 ,6 ]
Laing, K. [7 ,8 ]
McLeod, D. [9 ]
Verma, S. [10 ,11 ]
机构：
[1] Univ British Columbia, Dept Med, Vancouver, BC V5Z 4E6, Canada
[2] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada
[3] Natl Canc Ctr, Singapore, Singapore
[4] Duke NUS Grad Med Sch Singapore, Off Clin Sci, Singapore, Singapore
[5] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[6] Cross Canc Inst, Dept Med Oncol, Edmonton, AB T6G 1Z2, Canada
[7] Mem Univ Newfoundland, Dept Med, St John, NF, Canada
[8] Eastern Hlth, Canc Care Program, St John, NF, Canada
[9] Kaleidoscope Strateg, Toronto, ON, Canada
[10] Univ Toronto, Dept Med, Toronto, ON, Canada
[11] Sunnybrook Hlth Sci Ctr, Dept Med, Div Med Oncol Hematol, Toronto, ON M4N 3M5, Canada
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷 / 09期
关键词：
basal like; breast cancer; cancer treatment; targeted therapy; triple negative; systematic review; PACLITAXEL PLUS BEVACIZUMAB; ENDOTHELIAL GROWTH-FACTOR; BASAL-LIKE SUBTYPE; PHASE-II; PROGESTERONE-RECEPTOR; NEOADJUVANT CHEMOTHERAPY; PRECLINICAL MODELS; 1ST-LINE TREATMENT; ESTROGEN-RECEPTOR; RANDOMIZED-TRIAL;
D O I：
10.1093/annonc/mds067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Triple-negative breast cancer (TNBC) is a distinct subset of breast cancer (BC) defined by the lack of immunohistochemical expression of the estrogen and progesterone receptors and human epidermal growth factor receptor 2. It is highly heterogeneous and displays overlapping characteristics with both basal-like and BC susceptibility gene 1 and 2 mutant BCs. This review evaluates the activity of emerging targeted agents in TNBC. A systematic review of PubMed and conference databases was carried out to identify randomised clinical trials reporting outcomes in women with TNBC treated with targeted and platinum-based therapies. Our review identified TNBC studies of agents with different mechanisms of action, including induction of synthetic lethality and inhibition of angiogenesis, growth, and survival pathways. Combining targeted agents with chemotherapy in TNBC produced only modest gains in progression-free survival, and had little impact on survival. Six TNBC subgroups have been identified and found to differentially respond to specific targeted agents. The use of biological preselection to guide therapy will improve therapeutic indices in target-bearing populations. Ongoing clinical trials of targeted agents in unselected TNBC populations have yet to produce substantial improvements in outcomes, and advancements will depend on their development in target-selected populations.
引用
收藏
页码：2223 / 2234
页数：12
相关论文
共 50 条
  • [41] Targeting of breast cancer with non-oncology drugs - possible novel therapeutic option for triple-negative breast cancer
    Liedtke, C.
    Yan, K.
    Wu, Y.
    Hortobagyi, G. N.
    Symmans, W. F.
    Valero, V.
    Goette, M.
    Kiesel, L.
    Pusztai, L.
    CANCER RESEARCH, 2009, 69 (02) : 192S - 192S
  • [42] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
  • [43] Triple-Negative Breast Cancer
    Foulkes, William D.
    Smith, Ian E.
    Reis-Filho, Jorge S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1938 - 1948
  • [44] Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer
    Varshini, Magham Sai
    Krishnamurthy, Praveen Thaggikuppe
    Reddy, Ramakamma Aishwarya
    Wadhwani, Ashish
    Chandrasekhar, V. M.
    CURRENT CANCER DRUG TARGETS, 2025, 25 (01) : 3 - 25
  • [45] Recent advances in therapeutic strategies for triple-negative breast cancer
    Li, Yun
    Zhang, Huajun
    Merkher, Yulia
    Chen, Lin
    Liu, Na
    Leonov, Sergey
    Chen, Yongheng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [46] Therapeutic effects of TOPK inhibitor on triple-negative breast cancer
    Park, Jae-Hyun
    Miyamoto, Takashi
    Matsuo, Yo
    Nakamura, Yusuke
    CANCER RESEARCH, 2015, 75
  • [47] Novel therapeutic strategies for patients with triple-negative breast cancer
    Zhang, Jun-Fei
    Liu, Jia
    Wang, Yu
    Zhang, Bin
    ONCOTARGETS AND THERAPY, 2016, 9 : 6519 - 6528
  • [48] Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
    Xu, Na
    Li, Baohong
    Liu, Yong
    Yang, Cui
    Tang, Siqi
    Cho, William C.
    Huang, Zunnan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Triple-negative breast cancer
    Bartsch R.
    Ziebermayr R.
    Zielinski C.C.
    Steger G.G.
    Wiener Medizinische Wochenschrift, 2010, 160 (7-8) : 174 - 181
  • [50] TRIPLE-NEGATIVE BREAST CANCER: A SEARCH FOR NEW THERAPEUTIC TARGETS
    Walsh, S.
    Pierce, A.
    Flanagan, L.
    Quinn, C.
    Evoy, D.
    McDermott, E. W.
    Duffy, M. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2010, 179 : S347 - S347
12345